RHI Achieves Breakthrough in Genetic Hearing Loss Treatment

June 1st, 2021 – Rescue Hearing Inc. (RHI) has reached an exciting milestone in the fight against genetic hearing loss. Our latest research has unveiled a novel gene therapy technique designed to restore hearing in individuals affected by STRC gene mutations, a common cause of hereditary hearing impairment.

Targeting the Root Cause of Genetic Hearing Loss

This breakthrough therapy works by replacing defective genes with functional ones, effectively restoring inner ear hair cell function. The innovative approach addresses several critical aspects of STRC-related hearing loss:

Gene replacement therapy delivering functional STRC copies to inner ear cells
Restoration of stereocilin protein essential for proper hair cell function
Preservation of existing sensory structures while enhancing their functionality

Early preclinical trials have shown promising results, with treated subjects experiencing significant improvements in auditory function across multiple frequency ranges.

Path to Clinical Application

RHI is now preparing for the next phase of development, including regulatory approvals and patient recruitment for upcoming clinical trials. This methodical approach ensures both scientific rigor and patient safety as this groundbreaking treatment moves toward human applications.

“For too long, individuals with genetic hearing loss have had limited options. Our breakthrough paves the way for a potential cure, not just a temporary solution,” said Jim Ayala, CEO of RHI. “We are excited to move this research forward into clinical trials and bring hope to millions.”

Addressing a Major Cause of Hearing Loss

STRC mutations represent one of the most common genetic causes of hearing impairment worldwide. By specifically targeting this gene, RHI’s therapy has the potential to help a significant portion of the 466 million people globally who suffer from disabling hearing loss.

For More Information: